文献速递胃肠外科围术期管理与 ERAS

内镜治疗用于肥胖患者:系统评价与Meta分析

Endoscopic therapies for patients with obesity: a systematic review and meta-analysis.
PubMed 文献 · Surg Endosc · 2023-09-20

该研究检索了Embase、Cochrane Central和PubMed(2014年1月1日至2021年12月7日)的37项研究、15,639例患者,比较内镜减重治疗与非内镜治疗。结果显示内镜治疗减重优于生活方式干预,但不及减重手术;作者认为内镜治疗可能作为减重手术的替代选择。

要点

  • 胃内球囊6个月总体重减轻百分比为7.6-14.1%,生活方式干预为3.3-6.7%。
  • 内镜袖状胃成形术6个月总体重减轻百分比为4.7-14.4%,腹腔镜袖状胃切除术为18.8-26.5%。
  • 所有内镜干预的不良事件发生率均高于生活方式干预。

核心结论

  • 内镜治疗减重效果优于生活方式干预,但不及减重手术;作者认为内镜治疗可能作为减重手术的替代选择。

研究设计与样本

  • 系统评价与Meta分析,检索Embase、Cochrane Central和PubMed从2014年1月1日至2021年12月7日的文献,纳入搜索时获FDA或CE批准的内镜减重治疗对比非内镜治疗的37项研究、15,639例患者。
  • 采用Cochrane方法对临床试验和观察性数据的证据强度进行分级。

主要发现

  • 胃内球囊6个月总体重减轻百分比为7.6-14.1%,生活方式干预为3.3-6.7%;12个月分别为7.5-14.0%和3.1-7.9%。
  • 内镜袖状胃成形术6个月总体重减轻百分比为4.7-14.4%,腹腔镜袖状胃切除术为18.8-26.5%;12个月分别为4.5-18.6%和28.4-29.3%。
  • AspireAssist抽吸治疗12个月总体重减轻百分比为12.1-18.3%,生活方式干预为3.5-5.9%。
  • 所有内镜干预的不良事件发生率均高于生活方式干预。

临床怎么用

  • 作者认为内镜治疗可能作为减重手术的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is a major threat to public health and traditional bariatric surgery continues to have low utilization. Endoscopic treatments for obesity have emerged that offer less risk, but questions remain regarding efficacy, durability, and safety. We compared the efficacy of endoscopic bariatric procedures as compared to other existing treatments. METHODS: A literature search of Embase, Cochrane Central, and Pubmed was conducted from January 1, 2014 to December 7, 2021, including endoscopic bariatric therapies that were FDA or CE approved at the time of search to non-endoscopic treatments. Thirty-seven studies involving 15,639 patients were included. Primary outcomes included % total body weight loss (%TBWL), % excess body weight loss (%EBWL), and adverse events. Secondary outcomes included quality of life data and differences in hemoglobin A1C levels. Strength of clinical trial and observational data were graded according to the Cochrane methods. RESULTS: Intragastric balloons achieved greater %TBWL with a range of 7.6-14.1% compared to 3.3-6.7% with lifestyle modification at 6 months, and 7.5-14.0% compared to 3.1-7.9%, respectively, at 12 months. When endoscopic sleeve gastroplasty (ESG) was compared to laparoscopic sleeve gastrectomy (LSG), ESG had less %TBWL at 4.7-14.4% compared to 18.8-26.5% after LSG at 6 months, and 4.5-18.6% as compared to 28.4-29.3%, respectively, at 12 months. For the AspireAssist, there was greater %TBWL with aspiration therapy compared to lifestyle modification at 12 months, 12.1-18.3% TBWL versus 3.5-5.9% TBWL, respectively. All endoscopic interventions had higher adverse events rates compared to lifestyle modification. CONCLUSION: This review is the first to evaluate various endoscopic bariatric therapies using only RCTs and observational studies for evaluation of weight loss compared with conservative management, lifestyle modification, and bariatric surgery. Endoscopic therapies result in greater weight loss compared to lifestyle modification, but not as much as bariatric surgery. Endoscopic therapies may be beneficial as an alternative to bariatric surgery.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Weitzner ZN, Phan J, Begashaw MM, et al. Endoscopic therapies for patients with obesity: a systematic review and meta-analysis. Surg Endosc. 2023. PMID: 37730854. doi:10.1007/s00464-023-10390-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。